RESEARCH ARTICLE

Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database

Jie Zhou1,2, Zhenhua Hu1,2, Qijun Zhang1,2, Zhiwei Li1,2, Jie Xiang1,2, Sheng Yan1,2, Jian Wu1,2, Min Zhang1,2, Shusen Zheng1,2*

1 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China, 2 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

* shusenzheng@zju.edu.cn

Abstract

Background
De novo malignancies occur after liver transplantation because of immunosuppression and improved long-term survival. But the spectrums and associated risk factors remain unclear.

Aims
To describe the overall pattern of de novo cancers in liver transplant recipients.

Methods
Data from Scientific Registry of Transplant Recipients from October 1987 to December 2009 were analyzed. The spectrum of de novo cancer was analyzed and logistic-regression was used to identify predictors of de novo malignancies.

Results
Among 89,036 liver transplant recipients, 6,834 recipients developed 9,717 post-transplant malignancies. We focused on non-skin malignancies. A total of 3,845 recipients suffered from 4,854 de novo non-skin malignancies, including 1,098 de novo hematological malignancies, 38 donor-related cases, and 3,718 de novo solid-organ malignancies. Liver transplant recipients had more than 11 times elevated cancer risk compared with the general population. The long-term overall survival was better for recipients without de novo cancer. Multivariate analysis indicated that HCV, alcoholic liver disease, autoimmune liver disease, nonalcoholic steatohepatitis, re-transplantation, combined transplantation, hepatocellular carcinoma, immunosuppression regime of cellcept, cyclosporine, sirolimus, steroids and
tacrolimus were independent predictors for the development of solid malignancies after liver transplantation.

Conclusions
De novo cancer risk was elevated in liver transplant recipients. Multiple factors including age, gender, underlying liver disease and immunosuppression were associated with the development of de novo cancer. This is useful in guiding recipient selection as well as post-transplant surveillance and prevention.

Introduction
Liver transplantation is a life-saving therapy for end stage liver disease. The number of transplant cases has remained relatively stable in the United States in recent years, accompanied by improved graft survival and overall survival rates [1, 2]. However, the increased tumor burden due to longer life expectancy and use of immunosuppression regimens for preventing graft rejection, as well as cancer-related virus infection (including hepatitis B virus (HBV), hepatitis C virus (HCV), and Epstein-Barr virus (EBV)), has substantially impaired the overall survival of recipients.

Previous studies have demonstrated an overall 2 to 5-fold elevated risk of neoplasms among transplanted patients compared with the general population [3–11], probably cause by the immunosuppressive condition [11]. A recent study that analyzed data from the Scientific Registry of Transplant Recipients (SRTR) in linkage with multiple cancer registries observed an increased cancer risk in solid organ (including liver, kidney, lung, and heart) transplant recipients, with an incidence of 1,375 per 100,000 person-years (standardized incidence ratios (SIRs), 2.10) [12].

Malignancies in liver transplant recipients are also rising, with incidences varying from 2% to 16% [13, 14], which lead to elevated overall mortality rates in this population [15–17]. Indeed, post-transplant de novo malignancies-related death has become one of the most significant causes in liver transplant recipients [18–21].

Most of the previous studies have focused on de novo malignancies following kidney (or heart, lung) transplantation or the total transplant population. Although, a few studies have illustrated de novo tumor burden in liver transplant recipients, their data were either from a single center or limited by the relatively small sample size [22]. In addition, the follow-up lengths and transplant times varied. This may have led to a bias in cancer estimation. Therefore, evidence based on registry databases to access de novo malignancies in recipients following liver transplantation, as well as identifying possible associated risk factors, is needed.

Previously we have assessed the spectrum of de novo malignancies following liver transplantation based on our single center experience [23]. In order to further investigate the more detailed information based on general transplant population, we analyzed data from SRTR in this study to evaluate the profile of post-transplant de novo malignancies and associated predictors in liver transplant recipients.

Materials and Methods
This study used data from the SRTR, which includes data on all donors, wait-listed candidates, and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere. The Health Resources and Services Administration (HRSA), US Department of Health and Human Services, provides oversight for the activities of the OPTN and SRTR contractors [24]. Written informed consent
was given by participants. The SRTR as well as the Ethical Committee at Zhejiang University reviewed and approved this study.

We identified 101,117 liver transplant patients who underwent liver transplantation from October 1987 to December 2009. The study included only adult (> = 18 years) patients. As a result, 12,081 cases were excluded, and the remaining 89,036 cases were analyzed.

There were 9,717 post-transplant malignancies recorded for 6,834 recipients, including 2,968 skin cancers, 1,895 recurring cancers and 4,854 non-skin malignancies. For the purpose of this study, we focused on non-skin de novo malignancies, which included those suffering from either post transplant lymphoproliferative disorder (PTLD), donor-related cancer or de novo solid malignancies. Of the 6,834 recipients, 3,845 suffered from 4,854 de novo non-skin malignancies, including 1,098 de novo hematological malignancies, 38 donor-related cases, and 3,718 de novo solid-organ malignancies. Of note, we excluded the recipients who suffered from skin cancers and tumor recurrence. So the occurrence of diagnosed de novo malignancies included in the following analysis did not include any skin cancers or recurred tumors, which constituted a large part of the post-transplant malignancies recorded in the database.

We divided the liver transplant recipients into two groups: those with de novo non-skin malignancies were in the malignancy group (Malig group), and the remaining were in the non-malignancy group (Non-Malig group).

For immunosuppression analysis, the following immunosuppression regimens were assessed: tacrolimus, cyclosporin, sirolimus, mycophenolate mofetil, steroids (excluding patients treated with steroids for rejection episodes), and induction therapy with an anti-CD25 antibody or with thymoglobulin. Individuals who took the specific drug at transplant discharge and remained on the same drug maintenance protocol for at least 6 months post transplant (or until death) were considered at stable maintenance immunosuppression, and were taken further to analyze the impact of this specific drug.

We then assessed data on de novo malignancies occurrence and compared the data with those of the general population to calculate the SIR and to estimate the 95% confidential interval (CI). Overall survival rates were compared between Malig and Non-Malig group, first for all the recipients, and then for male and female recipients separately. To determine the predictors for de novo malignancies in the liver transplant population, we used a logistic analysis model.

**Statistical Analysis**

Numerical variables are described by means (plus the standard deviation, SD) and string variables by counts and percent. Expected malignancy cases were calculated by applying general population cancer rates (data derived from U.S. Cancer Statistics Working Group [25] and National Central Cancer Registry of China [26]) to transplant recipients. SIR for each cancer type was calculated by observed counts/ expected counts. Ninety-five percent CIs for the SIR were generated using an exact method that assumed the observed counts following a Poisson distribution. Kaplan-Meier method was used to compare the overall survival. Univariate analysis was performed and those with a significant difference were taken forward for logistic regression analysis to access independent predictors of incidence of cancers. Two-sided 95% CIs are described and tests were performed at the 5% level using a two-sided approach.

**Results**

**Demographics of the liver transplant population**

Among the 3,845 recipients who developed de novo non-skin malignancies, 66.71% (2,565 cases) were male. The mean age at the time of transplant was 53.38. The underlying liver diseases are depicted in Table 1. The top three underlying liver diseases were HCV (977 cases,
25.41%), alcoholic liver disease (ALD) (741 cases, 19.27%) and nonalcoholic steatohepatitis (NASH) or idiopathic liver disease (411 cases, 10.69%).

Baseline characteristics were compared between recipients who developed de novo malignancies and those who did not. Significant differences were observed in transplant year, recipient’s age, gender, race and blood type (all \( p < 0.001 \)). Recipients in the Malig group also had a higher re-transplant rate (\( p < 0.001 \)) and combined transplant rate (\( p < 0.001 \)). In terms of underlying diseases, recipients with HCC (\( p < 0.001 \)), HCV (\( p < 0.001 \)), ALD (\( p < 0.001 \)), acute hepatic necrosis (\( p = 0.001 \)), primary biliary cholangitis (PBC) (\( p = 0.004 \)), primary sclerosing cholangitis (PSC) (\( p < 0.001 \)) and NASH (\( p = 0.031 \)) were significantly different between those two groups. For immunosuppression regimes, significant differences were observed for patients maintained on cellcept (\( p = 0.047 \)), cyclosporine (\( p < 0.001 \)), steroids (\( p < 0.001 \)), sirolimus (\( p < 0.001 \)), tacrolimus (\( p < 0.001 \)) and thymoglobulin (\( p = 0.038 \)). Introduction with anti CD 25 was similar between those two groups (\( p = 0.907 \)). Detailed information is shown in Table 1.

Spectrum of de novo malignancies

Transplant recipients had more than 11 times cancer risk compared with the general population (SIR, 11.55 [95% CI, 11.23–11.88]). The elevated cancer risk was similar for male (SIR, 10.52 [95% CI, 10.16–10.88]) and female recipients (SIR, 11.69 [95% CI, 11.12–12.27]) (Table 2). When assessing cancer risk of recipients stratified by age, overall cancer risk was elevated in recipients younger than 65 years, with SIR = 14.91 (95% CI, 12.83 to 16.99) in those aged 18 to 34 years, SIR = 6.08 (95% CI, 5.75 to 6.41) in those aged 35 to 49 years and SIR = 2.23 (95% CI, 2.15 to 2.32) in those aged 50 to 64 years respectively. In recipients older than 65 years, cancer risk decreased (SIR = 0.71; 95% CI, 0.65 to 0.76) (S1 Table). Cancer risk was also assessed by transplant regions and investigated based on cancer statistics of Chinese population reported by the National Central Cancer Registry of China (S2 and S3 Tables).

De novo malignancies most commonly occurred in recipients with HCV (977 (3.53% of the analyzed population) recipients developing 1,199 de novo malignancies), followed by ALD (741 cases (5.98%) developing 948 de novo malignancies) and NASH (411 cases (3.91%) developing 525 de novo malignancies) (Fig 1).

When accessing each cancer type, SIRs were elevated for both hematological cancers (PTLD/lymphoma and leukemia) and solid organ cancers (including Kaposi’s sarcoma, brain, renal carcinoma, carcinoma of vulva, perineum or penis, carcinoma of the uterus, ovarian, testicular, esophagus, stomach, small intestine, pancreas, larynx, tongue, throat, thyroid, bladder, breast, prostate, colorectal, liver and lung). Cancer risk in the liver had the highest SIR in all liver transplant recipients (SIR, 77.94 [95% CI, 70.80–85.08]), and also for male recipients (SIR, 61.18 [95% CI, 54.79–67.57]) and female recipients (SIR, 95.54 [95% CI, 77.35–113.73]).

The most common anatomical sites for developing de novo solid organ malignancies were the lung (824 observed cases), followed by the liver (458 observed cases), prostate (316 observed cases) and colon-rectal tumor (313 observed cases). In male recipients, anatomical sites for developing de novo solid organ malignancies were similar to the general population, with lung (544 observed cases), liver (352 observed cases) and prostate (316 observed cases) ranking as the three most frequent types. In female recipients, lung cancer was also the most commonly encountered type (280 observed cases), but the next most common site was the breast (224 observed cases).

Detection of de novo malignancies during recipient follow up

The most frequent year to detect de novo malignancies during follow-up was the 2nd year post transplant, with 550 detected cases. The incidence increased in the first two years, with 315
Table 1. Overall characteristics of liver transplant recipients.

|                          | Non-malig (N = 85,191) | Malig (N = 3,845) | P value |
|--------------------------|------------------------|-------------------|---------|
| **Transplant Year**      |                        |                   |         |
| 1987–1994                | 15,791 (18.54%)        | 723 (18.80%)      | 0.673   |
| 1995–1999                | 17,605 (20.67%)        | 1,125 (29.26%)    | < 0.001 |
| 2000–2004                | 23,349 (27.41%)        | 1,151 (29.93%)    | 0.001   |
| 2005–2009                | 28,446 (33.39%)        | 846 (22.00%)      | < 0.001 |
| **Age**                  |                        |                   |         |
| 18–34                    | 7,192 (8.44%)          | 162 (4.21%)       | < 0.001 |
| 35–49                    | 28,282 (33.20%)        | 1,042 (27.10%)    | < 0.001 |
| 50–64                    | 42,595 (50.00%)        | 2,175 (56.57%)    | < 0.001 |
| >65                      | 7,122 (8.36%)          | 466 (12.12%)      | < 0.001 |
| **Gender**               |                        |                   |         |
| M                        | 53,840 (63.20%)        | 2,565 (66.71%)    | < 0.001 |
| **Race**                 |                        |                   |         |
| white                    | 64,465 (75.67%)        | 3,196 (83.12%)    | < 0.001 |
| African American or black| 6,968 (8.18%)          | 204 (5.31%)       | < 0.001 |
| Hispanic                 | 9,634 (11.31%)         | 302 (7.85%)       | < 0.001 |
| Asian                    | 3,341 (3.92%)          | 112 (2.91%)       | 0.001   |
| others                   | 783 (0.92%)            | 31 (0.81%)        | 0.539   |
| **Transplant Region**    |                        |                   |         |
| 1                        | 3,032 (3.56%)          | 207 (5.38%)       | < 0.001 |
| 2                        | 12,314 (14.45%)        | 422 (10.98%)      | < 0.001 |
| 3                        | 11,547 (13.55%)        | 494 (12.85%)      | 0.210   |
| 4                        | 7,204 (8.46%)          | 384 (9.99%)       | 0.001   |
| 5                        | 12,913 (15.16%)        | 454 (11.81%)      | < 0.001 |
| 6                        | 2,487 (2.92%)          | 173 (4.50%)       | < 0.001 |
| 7                        | 8,467 (9.94%)          | 525 (13.65%)      | < 0.001 |
| 8                        | 6,113 (7.18%)          | 332 (8.63%)       | 0.001   |
| 9                        | 6,661 (7.82%)          | 200 (5.20%)       | < 0.001 |
| 10                       | 7,098 (8.33%)          | 376 (9.78%)       | 0.002   |
| 11                       | 7,355 (8.63%)          | 278 (7.23%)       | 0.002   |
| **Blood Type**           |                        |                   |         |
| O                        | 36,754 (43.14%)        | 1,631 (42.42%)    | 0.378   |
| A                        | 33,312 (39.10%)        | 1,631 (42.42%)    | 0.012   |
| B                        | 10,963 (12.87%)        | 439 (11.42%)      | 0.009   |
| AB                       | 4,162 (4.89%)          | 194 (5.05%)       | 0.650   |
| **ABO_incompatible**     | 881 (1.03%)            | 34 (0.88%)        | 0.411   |
| **BMI**                  | < = 19.99              | 5,212 (6.12%)     | 227 (5.90%) | 0.603 |
|                          | 20.00–24.99             | 23,573 (27.67%)   | 1,093 (28.43%) | 0.311 |
|                          | 25.00–29.99             | 26,503 (31.11%)   | 1,207 (31.39%) | 0.709 |
|                          | > = 30.00               | 21,907 (25.72%)   | 991 (25.77%) | 0.941 |
| **Re-transplant**        | 7,846 (9.21%)          | 45 (1.17%)        | < 0.001 |
| **Combined Transplant**  | 3,973 (4.66%)          | 120 (3.12%)       | < 0.001 |
| **Primary Diagnosis**    | HCV                     | 26,680 (31.32%)   | 977 (25.41%) | < 0.001 |
|                          | HBV                     | 3,218 (3.78%)     | 128 (3.33%) | 0.167 |
|                          | Alcoholic liver disease| 11,644 (13.67%)   | 741 (19.27%) | < 0.001 |
|                          | Acute hepatic necrosis | 5,291 (6.21%)     | 186 (4.84%) | 0.001 |
|                          | Autoimmune              | 2,970 (3.49%)     | 136 (3.54%) | 0.862 |
|                          | Metabolic disease       | 2,405 (2.82%)     | 103 (2.68%) | 0.650 |
|                          | PBC                     | 4,728 (5.55%)     | 256 (6.66%) | 0.004 |
|                          | PSC                     | 5,494 (6.45%)     | 362 (9.41%) | < 0.001 |
|                          | NASH or idiopathic      | 10,088 (11.84%)   | 411 (10.69%) | 0.031 |
|                          | Other diagnosis          | 12,673 (14.88%)   | 545 (14.17%) | 0.237 |
|                          | HCC                     | 9,024 (10.59%)    | 506 (13.16%) | < 0.001 |

(Continued)
cases in the first six months and 415 cases in the first year. The incidence then decreased gradually, and at the longest follow up time (22 years), there were only two cases.

Compared with the general population, cancer risk increased from the first post-transplant year (SIR 1.16, 95% CI 1.04–1.27), gradually increased and reached its highest value highest years 6–10 of follow up (SIR 5.11, 95% CI 4.84–5.37). During the first 6 months post-transplant and after more than 16 years, cancer risk was decreased (SIR 0.80, 95% CI 0.71–0.89; SIR 0.62, 95% CI 0.52–0.72) (Fig 2).

Table 1. (Continued)

| Immunosuppression | Non-malig (N = 85,191) | Malig (N = 3,845) | P value |
|-------------------|------------------------|-------------------|---------|
| CellCept(Y/N)     | 17,031 (19.99%)/68,160 (80.01%) | 819 (21.30%)/3,026 (78.70%) | 0.047   |
| Cyclosporin(Y/N)  | 3,965 (4.65%)/81,226 (95.35%) | 311 (8.09%)/3,534 (91.91%) | < 0.001 |
| Sirolimus(Y/N)    | 882 (1.04%)/84,309 (98.96%) | 57 (1.48%)/3,788 (98.52%) | 0.010   |
| Steroids(Y/N)     | 28,500 (33.45%)/56,691 (66.55%) | 1,617 (42.05%)/2,228 (57.95%) | < 0.001 |
| Tacrolimus(Y/N)   | 28,539 (33.50%)/56,652 (66.50%) | 1,487 (38.67%)/2,358 (61.33%) | < 0.001 |
| Thymoglobulin(Y/N)| 1,750 (2.05%)/83,441 (97.95%) | 60 (1.56%)/3,785 (98.44%) | 0.038   |

Table 2. Overall View of de novo cancer in liver transplant recipients.

| All | SIR | 95% CI | male | SIR | 95% CI | female | SIR | 95% CI |
|-----|-----|--------|------|-----|--------|--------|-----|--------|
| Hematologic | PTLD/lymphoma | 1,041 | 52.90 | 56.12 | 49.69 | 713 | 47.88 | 51.40 | 44.37 | 328 | 53.75 | 59.57 | 47.94 |
| Leukemia | 57 | 5.16 | 6.50 | 3.82 | 44 | 4.88 | 3.55 | 6.54 | 13 | 4.11 | 2.18 | 7.05 |
| Donor related | | | | | | | | | | | | |
| Solid Organ | Kaposi's Sarcoma | 19 | 53.35 | 32.29 | 83.11 | 16 | 35.46 | 20.83 | 57.62 | 3 | 91.94 | 18.39 | 269.68 |
| Brain | 65 | 11.59 | 14.41 | 8.77 | 45 | 10.78 | 7.86 | 14.42 | 20 | 11.79 | 7.19 | 18.15 |
| Renal Carcinoma | 121 | 8.71 | 10.26 | 7.16 | 86 | 7.19 | 8.71 | 5.67 | 35 | 9.66 | 6.71 | 13.45 |
| Renal Carcinoma | 32 | 11.23 | 7.65 | 15.83 | 7 | 15.51 | 6.21 | 31.91 | 25 | 31.92 | 20.69 | 46.99 |
| Carcinoma of Vulva, Perineum or Penis | 41 | 1.89 | 1.35 | 2.56 | 41 | 5.15 | 3.69 | 6.98 |
| Ovarian | 34 | 3.05 | 2.11 | 4.27 | 34 | 8.34 | 5.76 | 11.65 |
| Testicular | 7 | 1.46 | 0.58 | 3.00 | 7 | 2.30 | 0.92 | 4.73 |
| Esophagus | 99 | 22.69 | 27.16 | 18.22 | 79 | 16.10 | 19.65 | 12.55 | 20 | 32.26 | 19.68 | 49.68 |
| Stomach | 65 | 10.90 | 13.55 | 8.25 | 43 | 8.11 | 5.87 | 10.92 | 22 | 14.66 | 9.19 | 22.12 |
| Small Intestine | 27 | 14.44 | 9.52 | 20.97 | 17 | 12.06 | 7.02 | 19.29 | 10 | 17.03 | 8.00 | 31.33 |
| Pancreas | 128 | 12.08 | 14.17 | 9.99 | 91 | 11.86 | 14.30 | 9.43 | 37 | 10.80 | 7.59 | 14.89 |
| Larynx | 67 | 19.29 | 23.92 | 14.67 | 57 | 14.86 | 18.72 | 11.00 | 10 | 20.43 | 9.60 | 37.59 |
| Tongue, Throat | 170 | 61.59 | 70.85 | 52.33 | 144 | 55.50 | 64.56 | 46.43 | 26 | 46.87 | 30.65 | 68.50 |
| Thyroid | 43 | 4.09 | 2.96 | 5.51 | 15 | 4.51 | 2.52 | 7.45 | 28 | 4.90 | 3.26 | 7.07 |
| Bladder | 109 | 5.80 | 6.89 | 4.71 | 92 | 4.38 | 5.28 | 3.49 | 17 | 5.66 | 3.30 | 9.06 |
| Breast | 235 | 4.00 | 4.51 | 3.49 | 11 | 13.93 | 6.84 | 24.95 | 224 | 5.63 | 6.36 | 4.89 |
| Prostate | 316 | 2.34 | 2.60 | 2.09 | 316 | 3.70 | 4.11 | 3.29 |
| Colorectal | 313 | 7.61 | 8.45 | 6.77 | 174 | 5.73 | 6.59 | 4.88 | 139 | 10.60 | 12.36 | 8.83 |
| Liver | 458 | 77.94 | 85.08 | 70.80 | 352 | 61.18 | 67.57 | 54.79 | 106 | 95.54 | 113.73 | 77.35 |
| Lung | 824 | 13.77 | 14.71 | 12.83 | 544 | 11.63 | 12.61 | 10.66 | 280 | 15.41 | 17.21 | 13.60 |
| Others | 545 | 381 | 164 | | | | | | | |
| Total | 4,854 | 11.55 | 11.88 | 11.23 | 3,260 | 10.52 | 10.88 | 10.16 | 1,594 | 11.69 | 12.27 | 11.12 |

doi:10.1371/journal.pone.0155179.t002
Post-transplant Survival

For recipients with de novo malignancies, the 1-year, 3-year, 5-year and 10-year overall survival was 94.5%, 80.8%, 69.6% and 43.6%, whereas for recipients without de novo malignancies, the corresponding overall survival was 82.5%, 74.5%, 68.6% and 54.5%, respectively (p < 0.001) (Fig 3A).

We also compared the overall survival between Malig and Non-malig group for male and female recipients respectively. The 1-year, 3-year, 5-year and 10-year overall survival was 93.8%, 79.5%, 67.3%, 40.5% for male recipients with de novo malignancies, and 82.9%, 74.5%, 68.3%, 53.5% for those without de novo malignancies (p < 0.001) (Fig 3B). The corresponding 1-year, 3-year, 5-year and 10-year overall survival for female recipients with de novo malignancies was 95.9%, 83.5%, 74.2%, 49.2%, and these were 81.8%, 74.6%, 69.3%, 56.0% for female without de novo malignancies (p = 0.001) (Fig 3C).
Risk factors for post-transplant de novo malignancies

In univariate analysis, 15 variables were associated with the development of neoplasia (S4 Table). Multivariate analysis identified the following variables as risk factors: underlying liver disease of HCV (HR 0.843, 95% CI 0.752–0.945, p = 0.003), ALD (HR 1.349, 95% CI 1.191–1.527, p < 0.001), autoimmune liver disease (HR 1.251, 95% CI 1.022–1.532, p = 0.03), NASH (HR 1.686, 95% CI 1.455–1.953, p < 0.001), re-transplantation (HR 0.128, 95% CI 0.095–0.172, p < 0.001), combined transplantation (HR 0.795, 95% CI 0.659–0.959, p = 0.016), HCC (HR 1.732, 95% CI 1.544–1.944, p < 0.001), immunosuppression regime of cellcept (HR 1.119, 95% CI 1.018–1.23, p = 0.02), cyclosporine (HR 1.513, 95% CI 1.317–1.737, p < 0.001), sirolimus (HR 1.396, 95% CI 1.061–1.838, p = 0.017), steroids (HR 1.167, 95% CI 1.081–1.26, p < 0.001) and tacrolimus (HR 1.271, 95% CI 1.168–1.383, p < 0.001) (Table 3).

Discussion

Mortality caused by post-transplant malignancies remains the leading cause of late death, significantly impairing long-term survival. Na et al. observed cancer-related mortality was significantly elevated compared with the general population (SMR = 2.83) [27]. Previous studies revealed a 2-fold increase in the rate of solid organ malignancies and a 30-fold or higher increase in the rate of PTLD. In this national registry based study, de novo malignancies occurred in 4.32% of liver transplant recipients. Cancer risk was one 10th elevated in transplant recipients compared with the general population during follow-up for 23 years. This is higher than previously reported SIRs based on either single or other population based studies, and probably results from the longer follow up time and large transplant population included in the current study, which provide a more thorough estimation of cancer risk in liver transplant recipients.
For single cancer risk (after excluding skin cancers and recurred tumors), liver cancer was most elevated for both male and female recipients, which agreed with a previous study by Engels et al. Thus, the high incidence of de novo liver cancer is cautionary, and intense screening after transplantation is important. In our study, all the cancers recorded had elevated SIRs. Previous studies also observed elevated GI malignancies, head and neck cancers, lung cancer, and genitourinary cancers in liver transplant recipients. Although the risks of prostate cancer and breast cancer were not reported to be elevated previously [5, 28], possibly because of intense surveillance for these cancers, our analysis still revealed a higher risk in liver transplant recipients. Thus, based on our study, a potential higher risk exists for these cancers, requiring more effective methods of intervention.

In our analysis, cancer risk was elevated in recipients less than 64 years old, and decreased by age stratification. In recipients older than 65 years old, cancer risk was lower than in the general population. This may be due to the increasing cancer incidence with age in the general population [29]. Moreover, older transplant recipients have lower post-transplant life expectancy compared with younger recipients, and may die before they suffer from a de novo malignancy. This may all contribute to the observation in our analysis.

Cancer risks also varied by follow-up year. De novo malignancy was most frequently observed in the 2nd year. And the cancer risk was mostly elevated during the 6th to 10th years. Engels et al. found that liver cancer had extraordinary risk in the first half year following transplantation [12]. Generally, de novo solid organ cancers occur more commonly after the first

| Table 3. Logistic regression analysis. |
|--------------------------------------|
| Sig. | OR | 95% CI |
|--------------------------------------|
| HCV vs. other diagnosis | < 0.001 | 0.843 | 0.752 | 0.945 |
| Alcoholic liver disease vs. other diagnosis | 0.03 | 1.251 | 1.022 | 1.532 |
| Autoimmune vs. other diagnosis | < 0.001 | 1.686 | 1.455 | 1.953 |
| NASH vs. other diagnosis | < 0.001 | 1.732 | 1.544 | 1.944 |
| HCC | < 0.001 | 2.426 | 2.15 | 2.738 |
| 1995–1999 vs. 1987–1994 | < 0.001 | 2.831 | 2.543 | 3.152 |
| 2000–2004 vs. 1987–1994 | < 0.001 | 2.124 | 1.928 | 2.339 |
| 2005–2009 vs. 1987–1994 | < 0.001 | 1.168 | 1.083 | 1.259 |
| Male vs. Female | < 0.001 | 0.128 | 0.095 | 0.172 |
| Re-transplantation | 0.016 | 0.795 | 0.659 | 0.959 |
| Combined-transplantation | < 0.001 | 0.379 | 0.314 | 0.458 |
| 35–49 vs. 18–34 | < 0.001 | 0.555 | 0.494 | 0.624 |
| 50–64 vs. 18–34 | < 0.001 | 0.808 | 0.727 | 0.897 |
| > 65 vs. 18–34 | 0.02 | 1.119 | 1.018 | 1.23 |
| CellCept | < 0.001 | 1.513 | 1.317 | 1.737 |
| Cyclosporin | 0.017 | 1.396 | 1.061 | 1.838 |
| Sirolimus | < 0.001 | 1.167 | 1.081 | 1.26 |
| Steroids | < 0.001 | 1.271 | 1.168 | 1.383 |

Fig 3. Comparison of overall survival between: A) Recipients with de novo cancers and those without de novo cancers; B) Male recipients with and without de novo cancers; C) Female recipients with and without de novo cancers.

doi:10.1371/journal.pone.0155179.g003
transplant year and increase by age, while PTLD has its greatest incidence in the first 12 to 18 months [30]. This data may aid surveillance procedures for liver transplant recipients.

A group of baseline characteristics were significantly different between Malig and Non-Malig group, indicating a possible intrinsic difference in the oncogenesis mechanism between these two groups. Previous studies demonstrated that age, immunosuppression, environmental exposures (i.e. smoking), infection and underlying liver disease were predictors for developing non-skin solid organ malignancies in liver transplant recipients. However, those studies were limited by their relatively small sample sizes. We performed logistic regression analysis based on our national database and observed that age, transplant year, underlying liver diseases, re-transplantation and combined transplantation, and immunosuppression were associated with de novo cancer.

Alcohol as a risk factor for several cancers, including oropharyngeal, laryngeal, esophageal, and liver malignancies, is well understood, and studies have proposed several mechanisms for this carcinogenesis. Our population-based analysis also revealed that alcohol exposure was an independent predictor that increased the cancer risk following transplantation. This agrees with a previous prospective study which analyzed the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database [22]. Other underlying liver diseases associated with increased de novo cancer risk included autoimmune liver disease, NASH and HCC. Importantly, according to a recent study by Charltono et al. [31], NASH has become the 3rd most common indication for liver transplantation in the United States. Although, this study demonstrated similar short survival rates for NASH compared with other liver diseases, the long-term outcome remains unknown. Thus, regarding the effects of de novo cancer on long-term survival, close monitoring during the post-transplant follow-up year in this sub-population is worth considering. Our analysis also demonstrated that recipients with HCV had the highest frequency of developing de novo cancer, yet logistic analysis revealed that HCV could reduce the risk of de novo malignancies. This may be because the transplant sample of HCV recipients was large, leading to higher detection frequency in this subgroup. Yet, among recipients with HCV, those who developed de novo cancer represented only 3.53% of all the HCV recipients, which is lower than those with ALD and NASH. This is consistent with the logistic analysis. Interestingly, re-transplantation and combined transplantation were also associated with a decreased cancer risk. This may reflect the different immune statuses in those recipients; however, the detailed mechanisms could not be determined based on the current study.

Immunosuppression regimes have long been recognized as one of the causes of post-transplant malignancies. The role of different immunosuppression protocols in transplant recipients has been explored. The mTOR inhibitors have strong anti-tumor effects compared with CNI-mediated immunosuppression in mouse models and in renal or heart transplant recipients [32–36]. However, there is limited data concerning their roles in liver transplant recipients. One study by Toso et al. revealed that sirolimus-based immunosuppression was associated with increased survival in recipients with HCC [37]. However, there is insufficient data on HCC recurrence; therefore, the antitumor/pro-tumor characteristics possibly underlying in different immunosuppression states cannot be fully defined. We found that all the immunosuppression regimes could elevate de novo cancer risk, with cyclosporin having the strongest potential effects. Based on our analysis, minimization of immunosuppression to the lowest tolerable level is recommended; however, it might not be helpful to convert the CNI regime to mTOR immunosuppression regime. Nonetheless, the benefits of reducing of skin malignancies and Kaposi’s sarcoma have been observed by immunosuppression reduction and cancer-specific treatments; however, the impact on solid tumors remains unknown. Thus, the effect of
immunosuppression on de novo cancer development in the liver transplant setting requires more evidence from clinical trials and basic researches.

There are some limitations in our study. Firstly, because this was a registry-based observational study, we identified independent predictors for developing de novo malignancies, but could not fully explain the underlying mechanisms. However, this was the first large population-based study to assess the risk factors associated with de novo malignancies following transplantation, as such, it could indicate directions for basic research in carcinogenesis in the transplant setting and also act as a guide for post-transplant surveillance in clinical practice. Secondly, variables of previously identified factors, such as smoking and infectious agents as risk factors for de novo malignancies are not complete for analysis from the SRTR database; therefore, we could not determine their effects on this large population. However, the elevated cancer risk known to be associated with infection (such as cancer of the liver, stomach and Kaposi’s Sarcoma) in this study reflected the fact that infection is an important factor that correlates with de novo malignancies.

In conclusion, de novo cancer risk was more than 11 times elevated in liver transplant recipients compared with the general population.Recipient age, underlying liver diseases, re-transplantation and combined transplantation and immunosuppression were all independent predictors for developing de novo cancer. Our findings will be useful in the liver transplant decision-making process in terms of donor allocation and immunosuppression selection, as well as promoting basic researches into the carcinogenesis mechanisms in the liver transplant setting.

Supporting Information
S1 Table. De novo malignancies by age.
(DOC)
S2 Table. De novo malignancies by region.
(DOC)
S3 Table. De novo malignancies based on Chinese population.
(DOC)
S4 Table. Univariate analysis.
(DOC)

Acknowledgments
Disclaimer: The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

The data reported here have been supplied by the Minneapolis Medical Research Foundation (MMRF) as the contractor for the Scientific Registry of Transplant Recipients (SRTR).

Author Contributions
Conceived and designed the experiments: SZ JZ. Performed the experiments: JZ QZ. Analyzed the data: ZL JW. Contributed reagents/materials/analysis tools: JX SY MZ. Wrote the paper: ZH JZ QZ.
References

1. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant. 2012; 12 Suppl 1:1–156. doi: 10.1111/j.1600-6143.2011.03886.x PMID: 22107249

2. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant. 2013; 13 Suppl 1:73–102. doi: 10.1111/ajt.12021 PMID: 23237697

3. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995; 60(2):183–9. PMID: 7829213

4. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10(6):1899–96. doi: 10.1111/j.1600-6143.2010.03864.x PMID: 20659094

5. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Yao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007; 7(4):941–8. PMID: 17331115

6. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7):1221–7. PMID: 14520450

7. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006; 296(23):2823–31. PMID: 17179459

8. Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000; 13 Suppl 1:S394–8. PMID: 11112040

9. Serraino D, Piselli P, Angeletti C, Minetti E, Pozzetto A, Civati G, et al. Risk of Kaposi’s sarcoma and other cancers in Italian renal transplant patients. Br J Cancer. 2005; 92(3):572–5. PMID: 15668710

10. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Yao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007; 7(4):941–8. PMID: 17331115

11. Grulich AE, van Leeuwen MT, Falster M, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59–67. PMID: 17617273

12. Engels EA, Pfeiffer RM, Fraumeni JF Jr., Kasakie BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306(17):1891–901. doi: 10.1001/jama.2011.1592 PMID: 22045767

13. Fung JJ, Jain A, Kwak EJ, Kusne D, Dvorcik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001; 7(11 Suppl 1):S109–18. PMID: 11689783

14. Jain A, Marcos A, Reyes J, Mazarriagos G, Kashyap R, Eghtesad B, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc. 2005; 37(2):1207–10. PMID: 15848671

15. Sheil AG. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc. 1995; 27(1):1247. PMID: 7878867

16. Lukes DJ, Herlenius G, Rizell M, Mjorstedt L, Bacman L, Olausson M, et al. Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant Proc. 2006; 38(8):2671–2. PMID: 17098034

17. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcaov J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001; 7(11):971–5. PMID: 11699033

18. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg. 2001; 181(5):475–9. PMID: 11448447

19. Baccarani U, Adami GL, Serraino D, Lorenzin D, Gambato M, Buda A, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc. 2009; 41(4):1303–5. doi: 10.1016/j.transproceed.2009.03.079 PMID: 19460546

20. Pruthi J, Medkiff KA, Ersarson KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7(6):811–5. PMID: 11552217

21. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant. 2003; 3(11):1407–12. PMID: 14529602

22. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009; 137(6):2010–7. doi: 10.1053/j.gastro.2009.08.070 PMID: 19766646
23. Yu S, Gao F, Yu J, Yan S, Wu J, Zhang M, et al. De novo cancers following liver transplantation: a single center experience in China. PLoS One. 2014; 9(1):e85651. doi: 10.1371/journal.pone.0085651 PMID: 24475047

24. Levine GN, McCullough KP, Rodgers AM, Dickinson DM, Ashby VB, Schaubel DE. Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant. 2006; 6(5 Pt 2):1228–42. PMID: 16613598

25. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available: http://www.cdc.gov/uscs.

26. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013; 25(1):10–21. doi: 10.3978/j.issn.1000-9604.2012.12.04 PMID: 23372337

27. Na R, Grulicher AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo Cancer-Related Death in Australian Liver and Cardiothoracic Transplant Recipients. Am J Transplant. 2013; 13(5):1296–304. doi: 10.1111/ajt.12192 PMID: 23464511

28. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997; 44(16):1172–81. PMID: 9261620

29. Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, et al. Solid-organ transplantation in older adults: current status and future research. Am J Transplant. 2012; 12(10):2608–22. doi: 10.1111/j.1600-6143.2012.04245.x PMID: 22958872

30. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006; 6(5 Pt 1):1017–24. PMID: 16611339

31. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011; 141(4):1249–53. doi: 10.1053/j.gastro.2011.06.061 PMID: 21726509

32. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Fiegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8(2):128–35. PMID: 11821896

33. Koehl GE, Andressy J, Guba M, Richter S, Kroemer A, Scherer MN, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004; 77(9):1319–26. PMID: 15167584

34. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant. 2008; 8(11):2212–8. doi: 10.1111/j.1600-6143.2008.02391.x PMID: 18785960

35. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87(2):233–42. doi: 10.1097/TP.0b013e3181927a41 PMID: 19155978

36. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006; 17(2):581–9. PMID: 16434506

37. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010; 51(4):1237–43. doi: 10.1002/hep.23437 PMID: 20187107